Sujal Shah
2019
In 2019, Sujal Shah earned a total compensation of $2.6M as Chief Executive Officer at Cymabay Therapeutics, a 32% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $153,000 |
|---|---|
| Option Awards | $1,889,125 |
| Salary | $510,000 |
| Other | $4,349 |
| Total | $2,556,474 |
Shah received $1.9M in option awards, accounting for 74% of the total pay in 2019.
Shah also received $153K in non-equity incentive plan, $510K in salary and $4.3K in other compensation.
Rankings
In 2019, Sujal Shah's compensation ranked 4,763rd out of 13,971 executives tracked by ExecPay. In other words, Shah earned more than 65.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,763 out of 13,971 | 66th |
Division Manufacturing | 1,774 out of 5,701 | 69th |
Major group Chemicals And Allied Products | 618 out of 2,200 | 72nd |
Industry group Drugs | 520 out of 1,886 | 72nd |
Industry Pharmaceutical Preparations | 392 out of 1,398 | 72nd |
Source: SEC filing on May 15, 2020.
Shah's colleagues
We found four more compensation records of executives who worked with Sujal Shah at Cymabay Therapeutics in 2019.
News
Cymabay Therapeutics CEO Sujal Shah's 2022 pay rises 16% to $2.6M
April 19, 2023
Cymabay Therapeutics CEO Sujal Shah's 2021 pay slips 16% to $2.2M
April 26, 2022
Cymabay Therapeutics CEO Sujal Shah's 2019 pay jumps 32% to $2.6M
May 15, 2020
Cymabay Therapeutics General Counsel Paul Quinlan receives $3M in 2018
April 26, 2019